Business Wire

CDR-Life Announces Initiation of CDR404 Phase 1 Trial for Treatment of Solid Tumors at ASCO

ZÜRICH--(BUSINESS WIRE)--CDR-Life Inc. today announced the initiation of enrollment for the Phase 1 trial of CDR404, its lead program in development as a precision immunotherapy for solid tumors.
Morningstar

LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories

VANCOUVER, BC / ACCESS Newswire / May 22, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce that Neuland Laboratories ...
ascopubs.org

Maintenance of patient-reported quality of life (EQ-5D-3L) post neoadjuvant relugolix prior to the initiation of prostate radiation therapy.

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of ...